Edition:
United States

Profile: Matinas BioPharma Holdings Inc (MTNB.N)

MTNB.N on New York Stock Exchange

0.67USD
23 Aug 2019
Change (% chg)

$-0.02 (-3.11%)
Prev Close
$0.69
Open
$0.65
Day's High
$0.69
Day's Low
$0.65
Volume
7,332
Avg. Vol
3,776
52-wk High
$1.49
52-wk Low
$0.40

Matinas BioPharma Holdings, Inc., incorporated on May 21, 2013, is a development stage biopharmaceutical company. The Company focuses on identifying and developing novel pharmaceutical products. The Company's technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, which is designed to make safer, more tolerable, less toxic and orally bioavailable. The Company's technology combines the use of lipids as active pharmaceutical ingredients (APIs) and the use of lipids in cochleate-shaped lipid-crystal nano-particle drug delivery vehicles. The Company’s product candidates include, MAT2203 and MAT2501.

MAT2203

The Company's anti-infective product candidate, MAT 2203, is an application of its cochleate delivery technology to a spectrum anti-fungal drug called amphotericin B. Amphotericin B is an IV administered drug used for treatment of systemic fungal infections resistant to triazoles and echinocandins, including resistant candidiasis, cryptococcal meningoencephalitis, and aspergillosis. The Company has completed two Phase 2 clinical trials with MAT2203.

MAT2501

The Company's MAT2501 is an orally administered, encochleated formulation of the spectrum IV-only aminoglycoside antibiotic agent amikacin, utilizes the Company's lipid-crystal, nanoparticle delivery technology. Amikacin is used to treat various types of chronic and acute bacterial infections, including nontuberculous mycobacteria (NTM) infections and various multidrug-resistant gram negative bacterial infections. IV-administered amikacin is associated with various side effects, including nephrotoxicity and ototoxicity (permanent loss of hearing). MAT2501 is specifically designed to provide targeted delivery of the potent antibiotic amikacin while providing a significantly improved safety and tolerability profile. In preclinical studies, MAT2501 demonstrated oral bioavailability, targeted delivery of amikacin directly to the site of infection in both pulmonary (lung), and disseminated NTM infections.

The Company competes with Pfizer, Inc., Merck & Co. Inc., Astellas Pharma US, Gilead Sciences, Inc., Novartis AG, Viamet Inc., Cidara Therapeutics, Sigma Tau, Insmed Incorporated, Tetraphase Pharmaceuticals, Inc., Achaogen, Inc., Cellceutix Corporation, Raptor Pharmaceuticals and The Medicines Company.

Company Address

Matinas BioPharma Holdings Inc

SUITE 302, 1545 ROUTE 206 SOUTH
BEDMINSTER   NJ   7921
P: +1908.4431860
F: +1302.6365454

Company Web Links